Drugs / ARM011
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07066397 | Jul 2025 → Apr 2028 expected | acute lymphoblastic leukemia | TriArm Therapeutics (Taiwan) Limited | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARM011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07066397 ↗ |
| Modality | Cell therapy | “ARM011 is an autologous, CD19 targeted CAR T-cell product” NCT07066397 ↗ |
| Route | Intravenous | “FIT-CD19-CAR-T (ARM011) administered intravenously (IV)” NCT07066397 ↗ |
| Target | CD19 | “ARM011 is an autologous, CD19 targeted CAR T-cell product” NCT07066397 ↗ |